Products (GTMPs): These are products that have as their principal intended action the modification of genetic material. They are used to treat or prevent diseases by inserting, altering, or removing genes within a patient’s cells.

Somatic Cell Therapy Medicinal Products (CTMPs): These products consist of cells or tissues that have been manipulated in vitro for therapeutic use. They are designed to treat, prevent or diagnose diseases through cellular interventions.

Tissue-engineered Products: These are products that involve the use of cells, with or without the addition of biomaterials, to regenerate, repair, or replace human tissues.

Understanding these categories sets the foundation for further distinctions between ATMPs and other product types, especially those classified as Human Cells, Tissues, and Cellular and Tissue-based Products (HCT/Ps), which fall under a different regulatory framework as outlined by the FDA.

Step 2: Distinguishing ATMPs from HCT/Ps

The ability to distinguish between ATMPs and HCT/Ps is critical, especially within the US regulatory environment. The FDA primarily focuses on whether a product is regulated under 21 CFR 1271 (HCT/Ps) or 21 CFR 312 (drugs). The distinction hinges on the concept of ‘minimal manipulation’ and ‘homologous use.’

Under FDA regulations, HCT/Ps can be classified under two sections: HCT/P 361 and HCT/P 351. The key differences are as follows:

• HCT/P 361: These products are exempt from premarket approval as long as they are minimally manipulated and intended for homologous use.
• HCT/P 351: Any product that does not meet the criteria for HCT/P 361 falls under this category and requires full FDA approval as they are considered drugs.

A product can qualify as an ATMP based on its manufacturing and intended use, where gene therapy and somatic cell therapy products will typically require substantial premarket approval, contrasting the HCT/P 361 classification. This crucial step often requires a comprehensive analysis of both the scientific and regulatory characteristics of the product.

Step 3: Analyzing Borderline Classification Scenarios

In many cases, product developers encounter complications regarding borderline classifications, particularly when their products have overlapping characteristics of ATMPs and HCT/Ps. Understanding and identifying product features can clarify which regulatory pathway to pursue.

Several factors influence this analysis, including:

• Method of manufacture: Determine if significant manipulation is involved in the preparation of the product, which could push it towards ATMP classification.
• Intended use: Evaluate the therapeutic intent of the product. If it aims to alter the biochemistry or physiology of the recipient, it is likely to be an ATMP.
• Biological origin: Trace the source of cells and tissues. If they are derived from genetically modified organisms, the product is more likely an ATMP.

Critical documentation such as manufacturing protocols, intended use letters, and risk assessments can assist in substantiating the classification claim. Clarifying these elements not only supports a better understanding of the regulatory classification but also aids in preparing the necessary applications for both FDA and EMA consultative pathways.

Step 4: Consultation with Regulatory Authorities

Engagement with the appropriate regulatory authorities is a vital step in confirming product classification and pursuing successful market access. Early interactions with the EMA and FDA can facilitate guidance and provide avenues to streamline the submission process. For EMA, engaging in the scientific advice process can clarify the classification and expected documentation to support a marketing authorization application.

For US products, initiating a pre-IND (Investigational New Drug) meeting with the FDA is equally essential, especially for products that straddle the line between HCT/Ps and ATMPs. The FDA offers guidance via meetings that can clarify complex scenarios, aiding sponsors in identifying the correct regulatory pathway.

Documentation to prepare for these consultations may include:

• Product description outlining the mechanism of action and intended use;
• Evidence from preclinical studies supporting classification arguments;
• Manufacturing process schemas to represent compliance with relevant standards;
• Risk assessments that outline potential regulatory challenges.

During consultation, it is crucial to remain open to feedback and guidance, as this can significantly impact the paths taken throughout product development and approval processes.

Step 5: Preparation of Regulatory Dossiers

Once classifications have been established through consultations, the next phase involves compiling regulatory dossiers that cater to both development plans and compliance expectations. The EU’s centralized authorization requires a comprehensive and well-structured Marketing Authorization Application (MAA) that emphasizes quality, safety, and efficacy.

In the US, the Informed Consent documentation, Investigational New Drug Application (IND), and subsequent Biologic License Application (BLA) must align with outlined clinical data demonstrating the designed product’s safety and efficacy. Here are some key components:

• Quality: Information on raw materials, manufacturing processes, and quality control measures must adhere to Good Manufacturing Practices (GMP).
• Non-Clinical Studies: Data demonstrating pharmacodynamics, pharmacokinetics, and preliminary safety profiles are crucial.
• Clinical Studies: Design and results of clinical trials that support efficacy and safety claims must be included, accompanied by ethical considerations such as informed consent.

While compiling the dossiers, keep in mind that alignment with ICH guidelines, particularly Good Clinical Practice (GCP), is non-negotiable, ensuring that all elements are compliant and ready for regulator review.

Step 6: Submission and Review Process

Upon completion of the preparation phase, submissions can begin. For EU submissions, either an MAA through the centralized procedure or a national procedure can be filed depending on the target member states. Ensure that all submissions include the required fees, followed by an acknowledgment of receipt from the EMA. For expedited designations, products may qualify under conditional marketing authorization or priority review, dependent on demo data analysis.

In the US, after the IND is submitted and reviewed, the FDA will send an acknowledgment letter. Following the successful IND period, the BLA submission can occur when the product reaches a sufficient development stage. This stage must be paired with data from clinical studies demonstrating safety and efficacy as mandated under 21 CFR 601.

During the review process, both agencies may request additional information or clarification. Timely responses to these requests are essential and often require substantial documentation and ongoing dialogue with regulatory officials. Prepare for potential outcomes ranging from full approval to additional clinical trials or amendments to applications based on reviewer feedback.

Step 7: Post-Approval Commitments and Monitoring

After obtaining approval, it is crucial to understand that regulatory responsibilities do not cease. ATMPs often require post-marketing commitments to ensure ongoing product safety and vigilance over long-term effects. Regular reporting must be conducted to the EMA and FDA, detailing any adverse events and conducting post-marketing studies as applicable.

Key actions include:

• Ongoing pharmacovigilance: Report serious adverse events (SAEs) to maintain compliance with Good Pharmacovigilance Practices (GVP).
• Periodic Safety Update Reports (PSURs): Submit updated reports at specified intervals conforming to local regulations.
• Annual Reports: Include any substantial changes in manufacturing processes or quality controls.

Regular engagement with the EMA and FDA through post-approval inspections and routine audits can ensure compliance while helping identify areas for product improvement and innovation.

Conclusion

The journey from product conception to market approval for ATMPs requires meticulous planning and understanding of the classification challenges that lie ahead. By following this step-by-step guide, regulatory professionals can effectively navigate the complexities of ATMP classification, facilitate successful submissions, and ensure compliance throughout product life cycles. Utilizing resources such as the EMA, FDA guidelines, and relevant ICH standards can provide further clarity and direction during this intricate process.